Comparison of Discriminative Ability of Bleeding Risk Criteria and Scores for Predicting Short- and Mid-Term Major Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention

Figures

• 

  Figure 1.. Study flowchart showing patient selection. ARC-HBR, Academic Research Consortium for High Bleeding Risk; HBR, high bleeding risk; J-HBR, Japanese version of the High Bleeding Risk; PRECISE-DAPT, Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.

• 

  Figure 2.. Prevalence of each criterion included in the ARC-HBR and J-HBR scores. ARC-HBR, Academic Research Consortium for High Bleeding Risk; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; ICH, intracranial hemorrhage; J-HBR, Japanese version of the High Bleeding Risk; LC, liver cirrhosis; NSAID, nonsteroidal anti-inflammatory drug.

• 

  Figure 3.. Kaplan-Meier analysis for the cumulative incidence of the primary outcome measure. (A) Kaplan-Meier analysis for major bleeding events between HBR and non-HBR groups according to J-HBR scores. (B) Kaplan-Meier analysis for major bleeding events between HBR and non-HBR groups according to ARC-HBR scores. (C) Kaplan-Meier analysis for major bleeding events between HBR and non-HBR groups according to PRECISE-DAPT score. (D) Landmark analysis within and beyond 30 days for major bleeding events between HBR and non-HBR groups according to J-HBR scores. (E) Landmark analysis within and beyond 30 days for major bleeding events between HBR and non-HBR groups according to ARC-HBR scores. (F) Landmark analysis within and beyond 30 days for major bleeding events between HBR and non-HBR groups according to PRECISE-DAPT scores. ARC-HBR, Academic Research Consortium for High Bleeding Risk; BARC, Bleeding Academic Research Consortium; HBR, high bleeding risk; J-HBR, Japanese version of the High Bleeding Risk; PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.

• 

  Figure 4.. Kaplan-Meier analysis for the cumulative incidence of major bleeding events stratified by each bleeding risk score. (A) Kaplan-Meier analysis for major bleeding events among J-HBR scores 0–0.5, 1–1.5, 2–2.5, and ≥3. (B) Kaplan-Meier analysis for major bleeding events among ARC-HBR scores 0–0.5, 1–1.5, and ≥2. (C) Kaplan-Meier analysis for the major bleeding events among PRECISE-DAPT scores 0–17, 18–24, and ≥ 25. (D) Landmark analysis within and beyond 30 days for major bleeding events among J-HBR scores 0–0.5, 1–1.5, 2–2.5, and ≥3. (E) Landmark analysis within and beyond 30 days for major bleeding events among ARC-HBR scores 0–0.5, 1–1.5, and ≥2. (F) Landmark analysis within and beyond 30 days for major bleeding events among PRECISE-DAPT scores 0–17, 18–24, and ≥25. ARC-HBR, Academic Research Consortium for High Bleeding Risk; J-HBR, Japanese version of the High Bleeding Risk; PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.

• 

  Figure 5.. Time-dependent receiver operating characteristic (ROC) curve analysis for predicting major bleeding events (BARC type 3 or 5 bleeding) according to the J-HBR, ARC-HBR, and PRECISE-DAPT scores. (A) Time-dependent ROC curve analysis for predicting major bleeding events within 30 days. (B) Time-dependent ROC curve analysis for predicting major bleeding events within 2 years. (C) Time-dependent ROC curve analysis for predicting major bleeding events between 30 days and 2 years. ARC-HBR, Academic Research Consortium for High Bleeding Risk; BARC, Bleeding Academic Research Consortium; J-HBR, Japanese version of the High Bleeding Risk; PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy; PPV, positive predictive value; NPV, negative predictive value.